We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance



Results:1-10 of 998

PTAB Upholds GILENYA Method of Treatment Patent, Prompting New ANDA Litigation
  • Jones Day
  • USA
  • July 30 2018

In Apotex Inc. v. Novartis AG, IPR2017-00854, Paper 109 (Jul. 11, 2018), the PTAB held that the claims of U.S. Patent No. 9,187,405 were not


La vicenda AvastinLucentis prossima all’epilogo. Un’infrazione antitrust che potrebbe trovarsi senza oggetto
  • De Berti Jacchia Franchini Forlani Studio Legale
  • European Union, Italy
  • July 25 2018

Nel prossimo autunno, il Consiglio di Stato sarà chiamato a decidere la controversia tra F. Hoffmann-La Roche Ltd (Roche), Roche SpA (Roche Italia)


Motions for Additional Discovery at the PTAB
  • Rothwell, Figg, Ernst & Manbeck, PC
  • USA
  • June 25 2018

The Patent Trial and Appeal Board (“PTAB”) rarely grants motions for additional discovery filed by a party in an inter partes review (“IPR”)


PTAB Denies Another IPR Petition Relating to Adalimumab
  • Rothwell, Figg, Ernst & Manbeck, PC
  • USA
  • June 14 2018

The Patent Trial and Appeal Board (“PTAB”) recently denied Sandoz’s petition for inter partes review (“IPR”) of claims 1-30 of AbbVie’s patent, U.S


Novartis and Amgen Announce FDA Approval of Aimovig
  • Rothwell, Figg, Ernst & Manbeck, PC
  • USA
  • May 23 2018

Last week, Novartis and Amgen announced the FDA approved Aimovig (erenumab) for the preventive treatment of migraine in adults. The FDA granted


CRISPR dust-up; compulsory licensing in China; Novartis CEO wants US reform, and more April's Life Sciences IP Round-up
  • IAM
  • USA, China, Global, India
  • May 7 2018

In this month’s round-up of life sciences-related patent news, we report on the year’s first pharma mega-merger, the latest developments in a


CJEU: concerted practice designed to reduce off-label use of a medicinal product to increase use of another
  • Accura Advokatpartnerselskab
  • Denmark, European Union
  • April 26 2018

In a recent judgment from January 2018 the Court of Justice of the European Union (CJEU) confirmed that concerted provision of misleading information


Side CAR-Ts
  • Bristows
  • United Kingdom, European Union
  • April 7 2018

Big pharma's interest in chimeric antigen receptor (CAR)-T therapies is clear: companies such as Novartis and Pfizer have been making large


Win or Go Home? Standing to Appeal PTAB Decisions Upholding Patentability to the Federal Circuit Before Submitting a Biosimilar Marketing Application
  • Patterson Belknap Webb & Tyler LLP
  • USA
  • April 6 2018

Biosimilar developers have been aggressive in filing petitions for inter partes reviews (IPRs) of biologics patents before the Patent Trial and Appeal


Additional Discovery of Clinical Trial Data in Inter Partes Review
  • Baker & Hostetler LLP
  • USA
  • March 30 2018

In Apotex, Inc. et al. v. Novartis AG (IPR 2017-00854, paper 47 dated Feb. 5, 2018), petitioner Apotex sought, and was granted, discovery of a Phase